Inmed pharmaceuticals strengthens patent portfolio with issuance of three u.s. patents

Inmed's intellectual property portfolio totals 13 patent families covering new chemical entities, formulations, manufacturing methods and methods of use vancouver, british columbia--(newsfile corp. - august 21, 2024) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced it has been issued three u.s. patents: one for its formulation and method of use in the treatment of epidermolysis bullosa and related connective tissue disorders, one for biosynthesis manufacturing processes and one for an ocular drug delivery formulation. the method of use patent, entitled "use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders" relates to inm-755 drug candidate which has completed a phase 2 clinical trial in the treatment of symptoms related to epidermolysis bullosa.
INM Ratings Summary
INM Quant Ranking